Dr. Xingyu Cao: CD7 CAR-T Combined with Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Improves Survival in r/r T-ALL/LBL Patients
Share
Introduction:
Relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) and T-cell lymphoblastic lymphoma (r/r T-LBL) have very poor prognosis with a five-year survival rate of less than 25%. Even with salvage treatment like allo-HSCT, the survival rate remains low at 14-30%. However, a new study led by Dr. Xingyu Cao from Ludaopei Hospital demonstrated that combining CD7 CAR-T therapy with allo-HSCT significantly improves survival in these patients.
Study Overview:
Dr. Cao and his team found that CD7 CAR-T therapy achieved high remission rates (over 90%) in r/r T-ALL/LBL patients, including those with central nervous system involvement or extramedullary disease. When these patients subsequently underwent allo-HSCT, the long-term survival rate doubled from 30% to around 60%.
Key Findings:
-
Effective Combination: CD7 CAR-T followed by allo-HSCT showed comparable outcomes to chemotherapy plus allo-HSCT, with no increased risks of infection or complications.
-
Long-Term Survival: The combination treatment improved survival rates, especially in younger patients, with a two-year survival rate exceeding 80%.
-
Safety: The therapy was safe, showing no significant increase in transplant-related risks, including infections or graft-versus-host disease (GVHD).
Implications for Future Treatment:
This approach provides a new, effective treatment strategy for r/r T-ALL/LBL, offering patients a significantly higher chance of long-term survival. Dr. Cao recommends this combination as a standard treatment for younger patients with r/r T-ALL/LBL.
Looking Ahead:
While CD7 CAR-T is still in clinical trials, the results are promising. Dr. Cao’s team is focusing on optimizing pre-treatment protocols to reduce transplant-related mortality further and improve survival rates.
Conclusion:
This study marks a significant breakthrough in the treatment of r/r T-ALL/LBL. CD7 CAR-T combined with allo-HSCT could become a game-changer, providing new hope for patients facing this challenging diagnosis.